Carol Wysham

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet · 2021 · 907 citations

Metabolic Syndrome, Diabetes Management, Diabetes +6

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Richard M. Bergenstal, Carol Wysham, Leigh MacConell et al. · The Lancet · 2010 · 605 citations

Weekly Versus Sitagliptin, Diabetes Management, Randomised Trial +8

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Carol Wysham, Thomas Blevins, Richard F. Arakaki et al. · Diabetes Care · 2014 · 371 citations

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda, Julio Rosenstock, Carol Wysham et al. · Diabetes Care · 2016 · 245 citations · Full text

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

Carol Wysham, Anuj Bhargava, Louis Chaykin et al. · JAMA · 2017 · 216 citations · Full text